Quick Takeaways
- LMMY - Exousia Bio, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2026.
- Headline metric: Return On Assets -323%.
- Info
- Financials
Exousia Bio, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
- Symbol
- LMMY on OTC
- Location
- St. Petersburg, FL
- Fiscal year end
- 31 May
- Latest financial report
- 17 Mar 2026
What Changed
- Return On Assets YoY change: <span class="text-red-600">-226%</span>.
- Most recent SEC facts end date: 17 Mar 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2026-03-17) highlights Return On Assets -322.9%, Current Ratio 0.0x, and Debt-to-equity 0.01x.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
19.2/100
Weak Confidence medium
Return On Assets
-323%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0x
- Debt to Equity
- 0.01x
Strengths
Debt-to-equity
Watchpoints
Return On Assets, Current Ratio, and Revenues YoY
Key metrics snapshot
Return On Assets
-323%
YoY: -226%
Industry median: -3.1% (n=38)
Current Ratio
0x
YoY:
Industry median: 1.21x (n=39)
Debt-to-equity
0.01x
YoY: -101%
Industry median: 0.4x (n=29)
Revenues YoY
-100%
YoY:
Industry median: -0.42% (n=33)
NetIncomeLoss YoY
-214%
YoY:
Industry median: 0.87% (n=37)
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Assets | -323% | -226% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 0x | |
| Debt-to-equity | 0.01x | -101% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | -100% | |
| NetIncomeLoss YoY | -214% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 73,500,000 | +845% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY